Amova Asset Management Americas Inc. Takes Position in BioNTech SE Sponsored ADR $BNTX

Amova Asset Management Americas Inc. acquired a new position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 77,694 shares of the company’s stock, valued at approximately $6,905,000.

A number of other large investors have also recently made changes to their positions in the company. Larson Financial Group LLC lifted its stake in BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the last quarter. EFG International AG acquired a new position in shares of BioNTech during the fourth quarter worth $29,000. Caitong International Asset Management Co. Ltd grew its stake in shares of BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after purchasing an additional 260 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after buying an additional 305 shares during the last quarter. Finally, Vestcor Inc acquired a new stake in BioNTech in the fourth quarter valued at $153,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Price Performance

BNTX stock opened at $92.16 on Tuesday. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $23.31 billion, a P/E ratio of -15.67 and a beta of 1.32. The business has a 50 day simple moving average of $91.32 and a 200-day simple moving average of $97.81. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, May 4th. The company reported ($2.26) earnings per share for the quarter, topping the consensus estimate of ($2.52) by $0.26. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The business had revenue of $136.71 million during the quarter, compared to the consensus estimate of $207.42 million. During the same quarter in the prior year, the firm earned ($1.73) earnings per share. The business’s quarterly revenue was down 35.4% compared to the same quarter last year. As a group, equities analysts anticipate that BioNTech SE Sponsored ADR will post -5.79 EPS for the current year.

BioNTech announced that its board has approved a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to repurchase up to 4.2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

Several research firms recently weighed in on BNTX. Berenberg Bank decreased their target price on BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Sanford C. Bernstein reiterated a “market perform” rating on shares of BioNTech in a research note on Friday, June 5th. UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $117.00 to $135.00 in a report on Wednesday, May 27th. Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Finally, Truist Financial upgraded shares of BioNTech to a “strong-buy” rating in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and an average price target of $129.12.

Insider Activity

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the sale, the chief operating officer owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. The trade was a 11.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by company insiders.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.